Last reviewed · How we verify
Liposom Forte
Liposom Forte is a Small molecule drug developed by Fidia Farmaceutici s.p.a.. It is currently FDA-approved. Also known as: Liposom.
Liposom Forte, marketed by Fidia Farmaceutici s.p.a., holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection afforded by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Liposom Forte |
|---|---|
| Also known as | Liposom |
| Sponsor | Fidia Farmaceutici s.p.a. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposom Forte CI brief — competitive landscape report
- Liposom Forte updates RSS · CI watch RSS
- Fidia Farmaceutici s.p.a. portfolio CI
Frequently asked questions about Liposom Forte
What is Liposom Forte?
Who makes Liposom Forte?
Is Liposom Forte also known as anything else?
What development phase is Liposom Forte in?
Related
- Manufacturer: Fidia Farmaceutici s.p.a. — full pipeline
- Also known as: Liposom
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing